Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicole Seebacher

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Australasian Journal of Dermatology|June 26, 2026
Immunotherapy for Melanoma: A Concise Clinical Review for Australasian PracticeAlexandra Stacy, Luca Wynn, Nicole Seebacher
Oncotarget|November 16, 2017
Novel strategies to prevent the development of multidrug resistance (MDR) in cancerJinglu Wang, Nicole Seebacher, Huirong Shi, et al.
Free Radical Biology & Medicine|May 8, 2016
Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistanceNicole Seebacher, Darius J R Lane, Des R Richardson, et al.
The Journal of Biological Chemistry|February 28, 2015
Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp)Patric J Jansson, Tetsuo Yamagishi, Akanksha Arvind, et al.
Journal of Medicinal Chemistry|August 7, 2012
Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivoDavid B Lovejoy, Danae M Sharp, Nicole Seebacher, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Australasian Journal of Dermatology|June 26, 2026
Immunotherapy for Melanoma: A Concise Clinical Review for Australasian PracticeAlexandra Stacy, Luca Wynn, Nicole Seebacher
Oncotarget|November 16, 2017
Novel strategies to prevent the development of multidrug resistance (MDR) in cancerJinglu Wang, Nicole Seebacher, Huirong Shi, et al.
Free Radical Biology & Medicine|May 8, 2016
Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistanceNicole Seebacher, Darius J R Lane, Des R Richardson, et al.
The Journal of Biological Chemistry|February 28, 2015
Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp)Patric J Jansson, Tetsuo Yamagishi, Akanksha Arvind, et al.
Journal of Medicinal Chemistry|August 7, 2012
Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivoDavid B Lovejoy, Danae M Sharp, Nicole Seebacher, et al.
Pageof 1